BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017

Conference Call and Webcast @ 8:30 a.m. Eastern Time Today NEW YORK and PETACH TIKVAH, Israel, March 8, 2018 -- (Healthcare Sales &Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technolog... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn , stem cell, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 12 June 2018 Source:Stem Cell Research Author(s): Julia Higelin, Alberto Catanese, Lena Luisa Semelink-Sedlacek, Sertap Oeztuerk, Anne-Kathrin Lutz, Julia Bausinger, Gotthold Barbi, Günter Speit, Peter M. Andersen, Albert C. Ludolph, Maria Demestre, Tobias M. Boeckers Mutations in genes coding for proteins involved in DNA damage response (DDR) and repair, such as C9orf72 and FUS (Fused in Sarcoma), are associated with neurodegenerative diseases and lead to amyotrophic lateral sclerosis (ALS). Heterozygous loss-of-function mutations in NEK1 (NIMA-related kinase 1) have also been rece...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
AbstractSporadic amyotrophic lateral sclerosis (sALS) is the most common form of ALS, however, the molecular mechanisms underlying cellular damage and motor neuron degeneration remain elusive. To identify molecular signatures of sALS we performed genome-wide expression profiling in laser capture microdissection-enriched surviving motor neurons (MNs) from lumbar spinal cords of sALS patients with rostral onset and caudal progression. After correcting for immunological background, we discover a highly specific gene expression signature for sALS that is associated with phosphorylated TDP-43 (pTDP-43) pathology. Transcriptome ...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
Amyotrophic lateral sclerosis (ALS) is a motor neuron (MN) disease characterized by the loss of MNs in the central nervous system. As MNs die, patients progressively lose their ability to control voluntary mov...
Source: Stem Cell Research and Therapy - Category: Stem Cells Authors: Tags: Research Source Type: research
Semin Neurol 2018; 38: 176-181 DOI: 10.1055/s-0038-1649338“Stem cell tourism” is defined as the unethical practice of offering unproven cellular preparations to patients suffering from various medical conditions. This phenomenon is rising in the field of neurology as patients are requesting information and opportunities for treatment with stem cells for incurable conditions such as multiple sclerosis and amyotrophic lateral sclerosis, despite their clinical research and experimental designation. Here, we review the recent trends in “stem cell tourism” in both the United States and abroad, and discus...
Source: Seminars in Neurology - Category: Neurology Authors: Tags: Review Article Source Type: research
Neurodegenerative diseases, such as Alzheimer ’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), affect millions of people every year and so far, there...
Source: Molecular Neurodegeneration - Category: Neurology Authors: Tags: Review Source Type: research
In conclusion, we here demonstrated for the first time that human TARDBP mutated MNs can be successfully obtained exploiting the reprogramming and differentiation ability of peripheral blood cells, an easily accessible source from any patient.
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Publication date: Available online 26 April 2018 Source:Stem Cell Reports Author(s): Aslam Abbasi Akhtar, Genevieve Gowing, Naomi Kobritz, Steve E. Savinoff, Leslie Garcia, David Saxon, Noell Cho, Gibum Kim, Colton M. Tom, Hannah Park, George Lawless, Brandon C. Shelley, Virginia B. Mattis, Joshua J. Breunig, Clive N. Svendsen Trophic factor delivery to the brain using stem cell-derived neural progenitors is a powerful way to bypass the blood-brain barrier. Protection of diseased neurons using this technology is a promising therapy for neurodegenerative diseases. Glial cell line-derived neurotrophic factor (GDNF) has prov...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
Publication date: Available online 17 May 2018 Source:Stem Cell Reports Author(s): Evangelos Kiskinis, Joel M. Kralj, Peng Zou, Eli N. Weinstein, Hongkang Zhang, Konstantinos Tsioras, Ole Wiskow, J. Alberto Ortega, Kevin Eggan, Adam E. Cohen Human induced pluripotent stem cell (iPSC)-derived neurons are an attractive substrate for modeling disease, yet the heterogeneity of these cultures presents a challenge for functional characterization by manual patch-clamp electrophysiology. Here, we describe an optimized all-optical electrophysiology, “Optopatch,” pipeline for high-throughput functional characterization ...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
FDA is cracking down on stem cell clinics that market unapproved products and don't meet good manufacturing practice requirements. On behalf of the agency, the Department of Justice filed two complaints in federal court this week seeking permanent injunctions against a Florida-based clinic and a California-based clinic.  “Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk. In some instances, patients have suffered serious and per...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
The use of autologous (or syngeneic) cells derived from induced pluripotent stem cells (iPSCs) holds great promise for future clinical use in a wide range of diseases and injuries. It is expected that cell replacement therapies using autologous cells would forego the need for immunosuppression, otherwise required in allogeneic transplantations. However, recent studies have shown the unexpected immune rejection of undifferentiated autologous mouse iPSCs after transplantation. Whether similar immunogenic properties are maintained in iPSC-derived lineage-committed cells (such as neural precursors) is relatively unknown. We de...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
More News: ALS | Brain | Conferences | Israel Health | Marketing | Middle East Health | Neurology | Pharmaceuticals | Stem Cell Therapy | Stem Cells